Navigation Links
Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
Date:2/5/2010

CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that its Board of Directors has elected John F. Crowley as Chairman of the Board in addition to his current role as Chief Executive Officer (CEO), effective immediately.  Mr. Crowley will succeed Donald J. Hayden, Jr., who will become the Lead Independent Director of the Board.

"The Board's decision to elect Mr. Crowley as Chairman of the Board reflects our confidence in his leadership and vision for Amicus.  Additionally, the Board recognized the value of the strong independent leadership provided by Mr. Hayden during his tenure as Chairman which will be preserved through his appointment as Lead Independent Director," stated Alexander Barkas, Ph.D., Amicus Board of Director and Member of Governance and Nominating Committee.

In his role as Chairman of the Board, Mr. Crowley will lead the Board's efforts in overseeing the development and implementation of the Company's strategic vision.  

As Lead Independent Director, Mr. Hayden will be responsible for, among other things, leading executive sessions of the Board's independent directors, advising the independent board committee chairs in fulfilling their responsibilities to the Board, assisting the Board and the Company's Officers in complying with Amicus' governance guidelines and overseeing the process of evaluating, developing and compensating the CEO.  A copy of the Lead Independent Director Charter describing in full Mr. Hayden's roles and responsibilities is available on the Amicus website at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

FOLD –G

SOURCE Amicus Therapeutics

RELATED LINKS
http://www.amicustherapeutics.com

'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  In Atlanta, it seems everyone has a chance to ... create an expressive and dynamic community unlike any other. The ... to it. With their newest salon in ... to carry on that tradition with a unique, fresh approach ... salon is the newest of 13 nationwide locations, each of ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017   ... Beyond Type 1, a not-for-profit advocacy and education group ... a grant from Beyond Type 1 to support ViaCyte,s ... and other insulin-requiring diabetes.  For more ... cell-derived cell replacement therapies with a focus on the ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017  PrimeVax ... , will be presenting at the Annual Biocom Global ... on March 2, at 11:15 AM, at the Torrey ... are thankful to the organizers at Biocom who have ... this international symposium of biotechnology companies, investors, and clinical ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/3/2017)... Feb. 3, 2017  Texas Biomedical Research Institute announced that ... Larry Schlesinger as the Institute,s new President and CEO. ... May 31, 2017. He is currently the Chair of the ... Center for Microbial Interface Biology at Ohio State University. ... new President and CEO of Texas Biomed," said Dr. ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):